Video

The Launch Pad: Why Platforms Matter For mRNA Therapeutic Development

Source: Cytiva

In this segment from the Bioprocess Online Live event, mRNA Update: Beyond Prophylactic Vaccines, Combined Therapeutics CSO Thomas Van Cott, Ph.D. walks us through the rationale for taking a platform approach to drive efficiencies in mRNA vaccine and therapeutic product development.

access the Video!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Advancing RNA? Subscribe today.

Subscribe to Advancing RNA X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Advancing RNA

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)

Cytiva